The Plecanatide Chronic Idiopathic Constipation (CIC) Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01429987
Recruitment Status : Completed
First Posted : September 7, 2011
Results First Posted : November 29, 2017
Last Update Posted : November 29, 2017
Information provided by (Responsible Party):
Synergy Pharmaceuticals Inc.

Brief Summary:
This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic Constipation (CIC).

Condition or disease Intervention/treatment Phase
Chronic Idiopathic Constipation Drug: plecanatide Other: Placebo Phase 2 Phase 3

Detailed Description:
This is a Phase IIb/III, randomized, double-blind, placebo-controlled, 12-Week, Repeat, Oral Dose Ranging, study to determine the safety and efficacy of plecanatide in patients with chronic idiopathic constipation (CIC). Subjects diagnosed with CIC via modified Rome III criteria will be screened against the inclusion and exclusion criteria for the study and enter a 2 Week pre treatment screening. During this phase patients will be required to call in their bowel movements (BM diary) as they occur, and call at least once daily to complete a patient diary of questions on their symptoms (Symptom Diary) associated with CC, as they will throughout the trial. Patients who complete at least 5 days of dosing per week, 6 of each 7 day period of BM diary calls, and continue to have less than 3 complete spontaneous movements per week (as well as meeting other inclusion and exclusion criteria) will be enrolled and randomized to one of three plecanatide doses 0.3 mg, 1.0 mg, and 3.0 mg or placebo. 880 patients will be randomized with the intent of having 200 patients per treatment group (each group the same size) included in efficacy analyses. All subjects receiving at least one dose of plecanatide or matching placebo will be included in the safety analyses.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 951 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study SP304-20210: A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Chronic Idiopathic Constipation
Study Start Date : October 2011
Primary Completion Date : December 2012
Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation
Drug Information available for: Plecanatide
U.S. FDA Resources

Arm Intervention/treatment
Experimental: plecanatide 0.3 mg
Subjects receive plecanatide 0.3 mg for 12 consecutive weeks
Drug: plecanatide
Subjects receive experimental study drug for 12 weeks.
Other Name: Trulance
Experimental: plecanatide 1.0 mg
Subjects receive plecanatide 1.0 mg for 12 consecutive weeks
Drug: plecanatide
Subjects receive experimental study drug for 12 weeks.
Other Name: Trulance
Experimental: plecanatide 3.0 mg
Subjects receive plecanatide 3.0 mg for 12 consecutive weeks
Drug: plecanatide
Subjects receive experimental study drug for 12 weeks.
Other Name: Trulance
Placebo Comparator: Placebo
Subjects receive placebo for 12 consecutive weeks
Other: Placebo
Subjects receive experimental study drug for 12 weeks.

Primary Outcome Measures :
  1. Overall Responder 9/12 Weeks [ Time Frame: 12 weeks ]
    A complete spontaneous bowel movement (CSBM) occurs at least 24 hours after laxative use and the patient reports a feeling of complete evacuation. A weekly responder will have 3 or more CSBMs and an increase of at least one CSBM from baseline. An overall responder is a patient who is a weekly responder for at least 9 of the 12 treatment weeks, including at least 3 of the last 4 weeks.

Secondary Outcome Measures :
  1. Reduction in Straining and Abdominal Symptoms Such as Pain, Discomfort and Bloating. [ Time Frame: 12 Weeks ]
    To demonstrate a reduction in straining and abdominal symptoms such as pain, discomfort and bloating as determined by patient reported outcome (PRO) measures collected via an Interactive Voice Response System (IVRS). To demonstrate an improvement in the hardness of stool, the frequency of spontaneous bowel movements, and a reduction in time to first bowel movement. To monitor and report all treatment emergent adverse events.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female aged 18-75, inclusive
  • Body Mass Index = 18-35 kg/m2, inclusive
  • Meets modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months. Note: For this trial, patients with manual maneuvers required for >25% of defecations will not be eligible for participation.
  • Less than 3 CSBMs per week at baseline and during pretreatment
  • Completed a colonoscopy in accordance with medical guidelines as appropriate, with no clinically significant findings
  • Patient is willing to discontinue use of supplemental fiber, laxatives, prescription and nonprescription medications, herbal or dietary supplements intended to treat constipation during the screening, pre-treatment, treatment and 2-week post-treatment periods
  • Willing to maintain a stable diet during the study.
  • Patients with hemorrhoids and/or diverticulosis (NOT diverticulitis) CAN be entered into the study.

Exclusion Criteria:

  • Loose stool (mushy) or watery (Bristol score- 6 or 7) stool in the absence of any laxative or prohibited medicine for > 25% of BMs during the 3 months prior to screening visit OR during the 14 day treatment period
  • Patient meets the Rome III criteria for Irritable Bowel Syndrome (IBS-C)
  • Active peptic ulcer disease not adequately treated or not stable
  • History of cathartic colon, laxative, enema abuse, or ischemic colitis.
  • Fecal impaction within 3 months of screening
  • Patient has had /has any: diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain
  • Unexplained and clinically significant "alarm symptoms" including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis.
  • Major surgery within 60 days of screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01429987

  Show 121 Study Locations
Sponsors and Collaborators
Synergy Pharmaceuticals Inc.

Additional Information:
Responsible Party: Synergy Pharmaceuticals Inc. Identifier: NCT01429987     History of Changes
Other Study ID Numbers: SP304-20210
First Posted: September 7, 2011    Key Record Dates
Results First Posted: November 29, 2017
Last Update Posted: November 29, 2017
Last Verified: October 2017

Keywords provided by Synergy Pharmaceuticals Inc.:
Chronic Idiopathic Constipation
Sign and Symptoms: Digestive

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Gastrointestinal Agents